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Disparities in pulmonary fibrosis care in the
United States: an analysis from the
Nationwide Inpatient Sample
Adam W. Gaffney1,2*, Steffie Woolhander3, David Himmelstein3 and Danny McCormick2,4
Abstract
Background: Idiopathic pulmonary fibrosis is a disease with high morbidity and mortality. Care for these patients,
including lung transplantation, may provide significant benefits, but is resource-intensive and expensive.
Disadvantaged patients with IPF may hence be at risk for receiving inferior care.
Methods: We analyzed data from the Nationwide Inpatient Sample, a database consisting of all hospitalizations
from a 20% sample of US hospitals. We identified adults hospitalized with IPF between 1998 and 2011 using ICD-9
codes. We assessed the effect of insurance coverage and socioeconomic status (SES) on lung transplantation, a
treatment that may improve survival. We also examined the effect of coverage and SES on mortality, as well as
discharge to inpatient rehabilitation and receipt of a lung biopsy, two markers of the intensity of care delivered. We
used multiple logistic regression to adjust for patient and hospital characteristics.
Results: We identified 148,877 hospitalizations that met our definition of pulmonary fibrosis. In the main adjusted
analyses, hospitalizations of patients with Medicaid (OR 0.30, 95% CI 0.16–0.57) or no insurance (OR 0.22, 95% CI 0.
07–0.72) were less likely to result in a lung transplantation compared to hospitalizations of those with non-Medicaid
insurance. Those of lower SES were also less likely to undergo transplantation, while hospitalized patients with
Medicaid and the uninsured were less likely to be discharged to inpatient rehabilitation or to receive a lung biopsy.
Conclusions: Among hospitalized patients with IPF, those with lower SES, Medicaid coverage and without
insurance were less likely to receive several clinical interventions.
Keywords: Disparities, Idiopathic pulmonary fibrosis, Lung transplantation
Background
Health disparities affect disadvantaged patients with a
range of pulmonary diseases [1–3]. Yet inequalities in care
for patients with interstitial lung diseases—inflammatory
and fibrotic conditions affecting the alveolar wall, such as
idiopathic pulmonary fibrosis (IPF) [4]—have not been
well studied.
IPF is a chronic interstitial lung disease with a progres-
sive, debilitating, and eventually deadly course. Its diag-
nosis requires a surgical lung biopsy in some but not all
patients [5]. No cure is available; however, new treat-
ments ameliorate the disease [6, 7]. Lung transplantation
may improve survival [8, 9], and current guidelines sup-
port its use in appropriate patients with IPF [5]. Pul-
monary rehabilitation is also recommended [5], with
some evidence pointing to improved quality of life and
exercise tolerance for such patients [10]. However, these
are expensive, resource-intensive interventions. Hence,
disadvantages patients with IPF may be at risk of receiv-
ing less care for their illness.
Using a large inpatient administrative database, we in-
vestigated disparities by insurance and socioeconomic
status (SES) for a range of clinical interventions and out-
comes among patients hospitalized in the United States
with pulmonary fibrosis.
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Methods
Study design and patient population
We used data from the Nationwide Inpatient Sample
(NIS) (Healthcare Cost and Utilization Project, Agency
for Healthcare Research and Quality), an administrative
claims database consisting (until 2012) of all hospitaliza-
tions drawn from a sample of 20% of US hospitals, and
then weighted to be nationally representative of all US
hospitalizations [11, 12].
We identified adults aged 18 years or older who were
hospitalized between 1998 and 2011 with probable IPF
based on diagnostic coding. In the NIS database, hospi-
talizations receive up to 15 ICD-9 codes. Previous inves-
tigations have identified subjects with IPF based on the
presence (prior to 2012) of an ICD-9 code for “idio-
pathic fibrosing alveolitis” (516.3), together with no
ICD-9 code for any other interstitial lung disease (ILD)
or ILD-related diagnosis (e.g. connective tissue disease)
other than the non-specific code for post-inflammatory
fibrosis (515) (see Additional file 1) [13–15]. This is
likely a conservative approach, since some subjects with
IPF may be coded with 515 (post-inflammatory fibrosis)
and not 516.3 [14]. Thus, for our main study analysis,
we followed Raghu et al. in excluding patients with diag-
nostic codes for other ILDs or ILD-related diagnoses
[13–15], yet followed others [16, 17] in including sub-
jects with either code 516.3 or 515. Because the ICD-9
coding for IPF changed in 2012, for consistency, we only
included hospitalizations from the years 1998–2011.
Our main analysis included all hospitalizations with ei-
ther code 516.3 or 515 as one of the first two diagnoses,
and without any secondary codes (see Additional file 1).
In a sensitivity analysis, we created a more narrowly de-
fined cohort consisting of hospitalizations with the more
specific code 516.3 as one of the top two diagnostic
codes, and without any secondary code apart from 515.
Data and measurements
We assessed the effects of insurance status on treatment,
based on the 6-category variable “expected primary
payer”, which we simplified into three-categories: (1)
“non-Medicaid insurance” (Medicare, private insurance,
or “other insurance”), (2) Medicaid, and (3) uninsured
(“self-pay” or “no charge”). Medicare is a universal fed-
eral public health insurance program that primarily
covers essentially all adults aged 65 and older, although
younger individuals who are disabled or who have
end-stage kidney disease are also eligible. Medicaid is a
means-tested federal-state public health insurance pro-
gram covering those of low-income, who traditionally
also belonged to certain groups (e.g., dependent children
and their parents, the disabled, and pregnant women).
In a sensitivity analysis, we excluded subjects aged 65
or older as well as younger patients with Medicare, and
recoded insurance status into a three-category variable:
(1) private insurance (“private insurance” or “other”), (2)
Medicaid, and (3) uninsured (“self-pay” or “no charge”).
We also assessed the effects of SES on treatments re-
ceived. We defined SES by the median income of the
ZIP Code in which the patient resided using the variable
ZIPINC_QRTZ. This variable was categorized into quar-
tiles with quartile 1 representing the lowest and quartile
4 representing the highest income levels. ZIP Code in-
come data were updated annually for years 2003 and be-
yond. However, for the years 1998–2002, a somewhat
different 4-category variable was used for the median in-
come of the patient’s ZIP Code, and which is based on
1999 demographics [18].
Our first outcome was lung transplantation during the
hospitalization, defined by having one or more proced-
ure codes for lung transplant (33.5, 33.50, 33.51, or
33.52). The second outcome was “death without trans-
plant” among non-transplanted patients.
The third outcome was discharge to a rehabilitation
facility For this, we generated a binary variable to indi-
cate transfer to a rehabilitation facility vs. any other dis-
position using the NIS variables “Dispub92” (for
pre-2008 discharges, which follows the UB-92 claim
form) or “Dispub04” (for discharges in 2007–2011,
which follows the UB-04 claim form). (The UB-92 and
UB-04 are billing forms submitted to insurers by health-
care facilities for reimbursement). Hospitalizations with
code 62 were considered to be discharged to a rehabili-
tation facility (see Additional file 1, note). Although pa-
tients discharged to a skilled nursing facility (a separate
code) sometimes also receive rehabilitative services fol-
lowing discharge, we opted to use the more specific dis-
charge disposition (i.e. code 62) as it likely reflects a
higher intensity of rehabilitative care [19]. Because no pa-
tients had a discharge disposition of code 62 earlier than
2001, earlier years were excluded for the rehabilitation
analysis, as were patients who died, had missing death
data, or were transplanted during the hospitalization.
Our fourth outcome was receipt of a thorascopic lung
biopsy (procedure code 33.20). This code did not exist
until 2007. Hence, earlier years were excluded from this
analysis. We do not assume that thorascopic lung biopsy
or inpatient rehabilitation are independent metrics of
quality. Rather, we view them as markers for the overall
intensity of care delivered, analogous to the approach of
Lyon et al. who investigated disparities in procedures re-
ceived by critically-ill patients [20].
We included individual and hospital-level characteris-
tics in our models because of their plausible role as con-
founders. Individual characteristics included gender, age
(on admission, treated as a continuous variable), race
(white, black, Hispanic, Asian or Pacific Islander, Native
American, or other), and year of discharge (treated as a
Gaffney et al. BMC Health Services Research  (2018) 18:618 Page 2 of 8
categorical variable). Comorbidities were coded using
the Healthcare Cost and Utilization Project (HCUP)
Elixhauser Comorbidity Software, which generates 29
binary comorbidity variables based on diagnostic codes
[21]. We then used HCUP software to generate the
Agency for Healthcare Research and Quality (AHRQ)
Elixhauser Comorbidity index for in-hospital mortality
for each hospitalization [21, 22], which we included in
our models as a continuous variable to adjust for disease
severity.
Models also included hospital characteristics, includ-
ing: census region (Northeast, Midwest, South, and
West), hospital location (rural vs. urban), hospital teach-
ing status (nonteaching vs. teaching), and hospital
bed-size by bed number (small, medium, or large). Hos-
pitalizations with missing data on exposure or covariates
were excluded.
Analysis plan
Baseline characteristics were determined using PROC
SURVEYFREQ or PROC SURVEYMEANS using the
SAS statistical software program (Cary, N.C). For each
of the four outcomes, we performed multivariate logistic
regression using the SAS procedure PROC SURVEYLO-
GISTIC, which accounts for the complex sample design.
All analyses were appropriately weighted using weights
supplied by the NIS to produce nationally representative
estimates [23]. Year of hospitalization was used as a
stratification variable. Standard errors were adjusted for
clustering by discharge hospital using the clustering and
sampling variables provided by the NIS. Because ana-
lyses were performed on subsets of the NIS, we followed
the steps outlined by HCUP documentation (Additional
file 1) [24] to include all hospitals and ensure appropri-
ate estimation of variances.
Because no lung transplantations occurred at non-teaching
or non-urban hospitals we excluded these variables from
analyses of lung transplantation. Notably, the validity of the
model fit was questionable for the analysis of rehabilitation
in both sensitivity analyses, and for VATS biopsy in the sensi-
tivity analysis that used the more narrow IPF definition.
This study received “exempt” status from the Institutional
Review Board of the Cambridge Health Alliance.
Results
Figure 1 outlines the cohorts used in our main analyses for
each of the four outcomes measures. There were 199,888
hospitalizations with codes 516.3 or 515 as the first or sec-
ond diagnostic code for the years 1998–2011 among adults
aged > = 18. After excluding 51,011 hospitalizations that
were missing data on any predictor variable or covariate,
148,877 hospitalizations remained. The more narrow defin-
ition of IPF, used for our sensitivity analysis, produced a
much smaller cohort (17,783 hospitalizations). The cohort
of those under age 65 without Medicare was also substan-
tially smaller (34,629 hospitalizations).
In our main cohort, an unweighted total of 808 pa-
tients (0.5% of 148,877) received a lung transplant, while
9569 died (6.5% of the 148,069 not transplanted), 1050
were transferred to a rehabilitation facility (1.2% of the
89,641 eligible survivors with data on disposition who
were not transplanted), and 1138 underwent a thora-
scopic lung biopsy (2.6% of the 43,740 eligible).
Table 1 displays the weighted characteristics of the
main cohort according to insurance status. The mean
age was 70.5 years and 55.7% were female. Patients with
Medicaid or no insurance were younger than other pa-
tients, were more likely to be a racial/ethnic minority
and live in lower income zip codes.
In the fully adjusted models (Table 2), patients with
Medicaid were less likely (OR 0.30, 95% CI 0.16, 0.57)
to undergo a lung transplant than those with
non-Medicaid insurance, as were those with no insur-
ance (OR 0.22, 95% CI 0.07, 0.72). Patients in the
lower three quartiles of median ZIP Code income
were less likely to receive a transplant than patients
in the highest quartile (OR for lowest vs. highest in-
come quartile, 0.46, 95% CI 0.32, 0.66).
Patients with Medicaid (OR 0.53, 95% CI 0.33, 0.85) or
no insurance (OR 0.41, 95% 0.18, 0.93) were less likely
to be discharged to a rehabilitation facility. Patients with
Medicaid were also less likely to undergo a VATS lung
biopsy (OR 0.46, 95% CI 0.35, 0.60), as were those with
no insurance (OR 0.52, 95% CI 0.35, 0.77).
There was no relationship between insurance status and
in-hospital death. Those in ZIP Code income quartile 1
(OR 0.93, 95% CI 0.87, 1.00) and quartile 2 (OR 0.91, 95%
CI 0.85, 0.97), but not those in quartile 3, had a reduced
odds of death as compared to quartile 4.
The results of analyses confined to those aged less
than 65 and without Medicare are shown in Table 3.
Those with Medicaid (OR 0.28, 95% CI 0.15, 0.51) and
the uninsured (OR 0.20, 95% CI 0.06, 0.63) continued to
have significantly lower odds of lung transplant, as well
as reduced odds of a VATS biopsy. Those in ZIP Code
income quartiles 1 and 2, but not quartile 3, continued
to have significantly reduced odds of lung transplant-
ation. However, the association between insurance and
rehabilitation transfer was no longer significant, al-
though the model for this outcome demonstrated ques-
tionable fit. There were no associations between
insurance status or zip income quartile and death.
In the sensitivity analysis using the narrower definition
of IPF (hospitalizations with ICD-9 code 516.3), a reduced
odds of transplantation (OR 0.24, 95% CI 0.11, 0.53) was
again seen for those with Medicaid, with a nonsignificant
trend towards a lower likelihood of transplantation
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amongst the uninsured (Additional file 2: Table S1). Those
in the lower three income quartiles continued to have a
significantly lower odds of transplant as well (quartile 1 v.
quartile 4 OR 0.46, 95% CI 0.29, 0.75). No associations
were seen between insurance status or SES and death,
VATS biopsy, or rehabilitation transfer, although the latter
two models had questionable fit.
Discussion
Among patients hospitalized with pulmonary fibrosis in
the US, those with Medicaid (a public insurance pro-
gram for those of low income), the uninsured, and pa-
tients of lower SES were much less likely to receive a
lung transplant. Those with Medicaid and the uninsured
were also less likely to be discharged to a rehabilitation
facility or undergo a lung biopsy.
Healthcare inequalities in patients with pulmonary dis-
ease [2] likely arise from several sources. Low SES is
itself associated with lower pulmonary function, which
may stem from a variety of exposures [25–27]. However,
unequal healthcare access may also be a factor. Unin-
sured patients with lung cancer are less likely to re-
ceive potentially curative therapy [3], while those with
cystic fibrosis die at a younger age [28]. People with
asthma who are uninsured, poor, black, or Hispanic
have inferior healthcare access and worse outcomes
[1, 29, 30]. Children with Medicaid are more likely
than privately insured children to be denied an ap-
pointment to see a specialist—including pulmonary
specialists [31]. And among adults with cystic fibrosis,
Medicaid coverage and low SES are independently as-
sociated with reduced odds of being accepted onto a
lung transplant waiting list [32]. Non-population
based studies also suggest that racial disparities may
impact patients with IPF, including in the transplant-
ation process [33–36].
Fig. 1 Flow chart of main study population formation with outcomes
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For other organs, evidence suggests racial disparities
throughout the transplantation process [37–39]. For in-
stance, among individuals on a liver transplant waiting list,
Hispanics are less likely to go on to receive an organ [37].
And with respect to insurance-related disparities, a study
using NIS data found that whereas organ donors are more
likely to be uninsured than other hospitalized patients,
organ recipients were virtually always insured [40].
Our study has some limitations. While the NIS provided
a very large, nationally representative sample—which
allows population-based assessment of rare events like
transplantation—it represents hospitalizations, not indi-
vidual patients. Thus, a factor that led to increased
hospitalizations among disadvantaged IPF patients could,
by increasing the denominator (i.e. the number of admis-
sions per patient), confound our results. However, given
the very low ORs of transplantation among the uninsured
and those with Medicaid, any such confounder would
have to increase total hospitalizations several-fold to ex-
plain the observed disparities. Moreover, evidence sug-
gests that the uninsured are actually less likely to be
hospitalized than the insured [41], which would tend to
bias our results towards the null, at least for the
uninsured.
Our findings do not necessarily demonstrate “with-
in-hospital” disparities. The disparities we observed
Table 1 Characteristics of patients hospitalized with pulmonary fibrosis stratified by insurance statusa
Total Non-Medicaid
insurance (91.6%)
Medicaid insurance (5.7%) Uninsured (2.1%)
Age (years) 70.5 71.9 54.6 53.8
Female 55.7% 55.3% 62.8% 50.4%
Race
White 78.2% 81.0% 42.7% 52.2%
Black 8.7% 7.6% 22.3% 19.7%
Hispanic 8.8% 7.5% 24.6% 19.7%
Asian or Pacific 1.9% 1.7% 4.8% 2.4%
Islander
Native American 0.4% 0.4% 0.9% 0.6%
Other 2.1% 1.9% 4.6% 5.4%
Income Quartile of Zipcode
1st 27.3% 26.1% 43.6% 37.5%
2nd 26.4% 26.4% 26.8% 28.9%
3rd 24.2% 24.6% 18.7% 20.9%
4th 22.1% 23.0% 10.9% 12.6%
Hospital Region
Northeast 22.5% 22.5% 22.9% 18.3%
Midwest 17.0% 17.4% 12.1% 12.4%
South 42.0% 42.0% 37.3% 57.4%
West 18.5% 18.1% 27.7% 11.9%
Hospital Location
Rural 13.7% 14.0% 10.0% 11.8%
Urban 86.3% 86.0% 90.0% 88.2%
Hospital Teach
Nonteaching 59.1% 60.0% 48.5% 48.9%
Teaching 40.9% 40.0% 51.5% 51.1%
Bedsize of hospital
Small 12.3% 12.5% 10.1% 12.7%
Medium 26.0% 25.9% 26.7% 25.8%
Large 61.7% 61.6% 63.2% 61.5%
AHRQ Elixhauser Comorbidity Index 4.6 4.7 3.7 2.6
aNationwide estimates based on weights supplied by NIS
Gaffney et al. BMC Health Services Research  (2018) 18:618 Page 5 of 8
could also result from the fact that, as compared to
more disadvantaged patients, advantaged patients may
be more likely to be admitted (or transferred) to hos-
pitals that provide a higher intensity of care (i.e. “be-
tween hospital” disparities). However, this was our
outcome of interest, since disadvantaged patients with
IPF may not be referred to lung transplantation cen-
ters to begin with.
Another limitation was our measure of SES, which
was based on ZIP code median income. Area-level me-
dian income describes only one component of SES. Fam-
ily income, wealth, and education are other measures of
SES that could potentially have different associations
with our outcomes of interest, although this was not
something we could evaluate in this study.
Since we lacked patient level data on the severity of
IPF, another potential concern is that the lower observed
rates of lung transplantation for disadvantaged patients
reflect a lower severity of pulmonary illness in these
groups. While we controlled for age and Elixhauser co-
morbidities, the possibility of residual confounding by
pulmonary disease severity persists. However, there is no
clear biological rationale why disadvantaged patients
should have less severe lung disease. Moreover, if they
did, we would expect lower in-hospital mortality, which
was overall not the case (the slightly reduced odds ratios
for death seen for two of the zip income quartiles were
not observed in sensitivity analyses).
We also found that those with Medicaid and the unin-
sured were less likely to be transferred to inpatient pulmon-
ary rehabilitation or to have a VATS biopsy. Pulmonary
rehabilitation is clinically beneficial [10] for some patients
and is recommended for IPF [5]. Although outpatient re-
habilitation is much more typical, differences in transfer to
inpatient rehabilitation facilities nonetheless can be seen as
a disparity in treatment. Although lung biopsy is not neces-
sary in all patients with interstitial lung disease (and in
some instances might reflect overtreatment), lower rates of
Table 2 Adjusted odds of four outcomes in IPF patients (ICD9 516.3 or 515)a
Lung Transplant Death Rehabilitation Transfer VATS Biopsy
Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value
Insurance
Non-medicaid Reference Reference Reference Reference
Medicaid 0.30 (0.16, 0.57) < 0.001 1.00 (0.89, 1.12) 0.95 0.53 (0.33, 0.85) 0.01 0.46 (0.35, 0.60) < 0.001
Uninsured 0.22 (0.07, 0.72) 0.01 1.12 (0.92, 1.35) 0.26 0.41 (0.18, 0.93) 0.03 0.52 (0.35, 0.77) < 0.01
ZIP Income Quartile
Quartile 1 0.46 (0.32, 0.66) < 0.001 0.93 (0.87, 1.00) 0.04 1.16 (0.92, 1.45) 0.21 1.01 (0.81, 1.25) 0.96
Quartile 2 0.56 (0.43, 0.73) < 0.001 0.91 (0.85, 0.97) < 0.01 1.00 (0.80, 1.24) 0.97 1.09 (0.90, 1.33) 0.38
Quartile 3 0.71 (0.57, 0.89) < 0.01 0.96 (0.90, 1.02) 0.19 1.11 (0.90, 1.36) 0.33 0.98 (0.81, 1.18) 0.81
Quartile 4 (Highest) Reference Reference Reference Reference
aAnalyses of death, rehab, and VATS were adjusted for age, race, gender, insurance, year, zip income quartile, hospital region, hospital location, hospital teaching
status, hospital bedsize, and AHRQ Elixhauser Comorbidity index for in-hospital mortality. Analyses of lung transplantation were adjusted for these same variables,
but not hospital teaching status nor urban/rural location, because the proportion of lung transplantations exhibiting these characteristics was either 0% or 100%
Table 3 Sensitivity Analysis: Adjusted odds of four outcomes among persons age < 65 (ICD9 516.3 or 515)a
Lung Transplant Death Rehabilitation Transferb VATS Biopsy
Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value Odds Ratio (95% CI) P-Value
Insurance
Non-medicaid Reference Reference Reference Reference
Medicaid 0.28 (0.15, 0.51) < 0.001 0.96 (0.82, 1.12) 0.57 0.78 (0.44, 1.38) 0.39 0.43 (0.32, 0.56) < 0.001
Uninsured 0.20 (0.06, 0.63) 0.01 0.84 (0.66, 1.08) 0.18 0.45 (0.16, 1.25) 0.12 0.50 (0.34, 0.75) < 0.01
ZIP Income Quartile
Quartile 1 0.50 (0.34, 0.72) < 0.001 0.96 (0.81, 1.13) 0.60 1.04 (0.53, 2.04) 0.91 1.29 (0.97, 1.73) 0.08
Quartile 2 0.63 (0.47, 0.84) <.01 0.87 (0.74, 1.02) 0.08 1.30 (0.73, 2.31) 0.38 1.14 (0.88, 1.49) 0.32
Quartile 3 0.81 (0.64, 1.03) 0.09 0.96 (0.82, 1.12) 0.57 1.24 (0.69, 2.22) 0.47 1.05 (0.81, 1.36) 0.74
Quartile 4 (Highest) Reference Reference Reference Reference
aAnalyses of death, rehab, and VATS were adjusted for age, race, gender, insurance, year, zip income quartile, hospital region, hospital location, hospital teaching
status, hospital bedsize, and AHRQ Elixhauser Comorbidity index for in-hospital mortality. Analyses of lung transplantation were adjusted for these same variables,
but not hospital teaching status and urban/rural location, because the proportion of lung transplantations exhibiting these characteristics was either 0% or 100%
bThe analysis for rehabilitation transfer demonstrated questionable model fit
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biopsies suggest that care decisions for hospitalized patients
with pulmonary fibrosis may, in part, be based on insurance
status rather than clinical need. Finally, the overall absence
of consistent disparities in death is not surprising given the
lack of evidence demonstrating that any specific therapy
improves survival for hospitalized patients with IPF.
What should pulmonologists make of these findings?
To some extent, it is not surprising that uninsured pa-
tients receive fewer lung transplantations [42]. Trans-
planting a patient who is unable to obtain
immunosuppressive medications following transplant
could actually cause more harm than good. However,
this does not mean that such disparities are justifiable.
Similarly, the reduced odds of transplant among patients
with Medicaid insurance—similar to what has been seen
in patients with cystic fibrosis [32]—is troubling, par-
ticularly given that this program covers almost 75 mil-
lion Americans [43]. Our findings reinforce the urgency
of physician advocacy for health coverage that is not
only universal, but equal [44].
There is evidence that “single tier” health insurance
systems may indeed be more equitable [45]. For in-
stance, a study of patients referred to kidney transplant
clinics in the Veterans Administration Health Care sys-
tem found no differences by race in the time to accept-
ance of a kidney transplant [46]. And a recent study
comparing patients with cystic fibrosis in the US with
those in Canada—which has a single-payer system—
found that the Canadians lived a decade longer, and also
received more transplants [47].
Conclusions
We found that in the United States, hospitalized individ-
uals with idiopathic pulmonary fibrosis who had no in-
surance, public insurance (Medicaid), or who were from
lower socioeconomic status areas were less likely to re-
ceive several clinical interventions. Clinical pulmonolo-
gists should advocate for more equitable access to lung
transplant, and all other treatments, both within our in-
stitutions and our society [44].
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